Navigation Links
Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program
Date:12/2/2008

BIRMINGHAM, Ala., Dec. 2/PRNewswire-USNewswire/ --Southern Research Institute -- a not-for-profit scientific organization that conducts basic and applied research in the areas of preclinical drug discovery and development, advanced engineering, environmental and energy production -- today announced that it has been awarded a subcontract from Black & Veatch to help support the U.S. Department of Defense's Biological Threat Reduction Program (BTRP) in the Ukraine.

The award is expected to generate up to $37 million in revenues for Southern Research over the next five years. "We are honored that Black & Veatch has selected our Southern Research team to provide support for such an important global program," said John A. "Jack" Secrist III, Ph.D., president and CEO of Southern Research Institute. "Working with Black & Veatch on the Ukraine task order will allow Southern Research to not only contribute to the safety and well-being of the United States, but to use our knowledge and expertise for global safety as well."

As the prime integrating contractor, Black & Veatch will design, engineer and deploy systems, processes and technologies to further strengthen reporting, detection and response capabilities. Southern Research will provide a wide range of scientific consulting in the design and implementation of modern diagnostic laboratories throughout the Ukraine. Additionally, Southern Research will facilitate collaborative research projects conducted by US-Ukraine interdisciplinary teams. The Southern Research biological threat reduction program will be managed by Mary Guttieri, Ph.D., based in Washington DC, in conjunction with William Severson, Ph.D., and Colleen B. Jonsson, Ph.D., based in Birmingham, Ala.

The Defense Threat Reduction Agency (DTRA), the BTRP's implementer, awarded Black & Veatch, a leading global engineering consulting and construction company, one of th
'/>"/>

SOURCE Southern Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
2. USAID Assistant Administrator Hess Travels to Southern Africa
3. Southern Research Institutes Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding
4. MIT Holding, Inc. signs partnership agreement with Georgia Southern University
5. Angel Flight West Recognizes Southern California Pilots at 24th Anniversary
6. Southern California Wildfires Continue to Threaten Residential Areas
7. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
8. VA Remains Open for Care for Southern California Vets
9. Red Cross Receives $250,000 From Wal-Mart to Assist With Southern California Wildfire Relief Efforts
10. The Salvation Army Responds to Immediate Needs of Survivors and Relief Workers in Southern California Wildfires
11. CNA/NNOC Nurse Volunteers Deployed to Southern California Firestorm
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 1Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 2Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 3Intrinsic Therapeutics Barricaid and Magellan Spine Technologies DART to Drive European Annulus Repair Market 50256 1Intrinsic Therapeutics Barricaid and Magellan Spine Technologies DART to Drive European Annulus Repair Market 50256 2Intrinsic Therapeutics Barricaid and Magellan Spine Technologies DART to Drive European Annulus Repair Market 50256 3Horizon Therapeutics Names Dr Jeffrey W Sherman Executive Vice President and Chief Medical Officer 12821 1Horizon Therapeutics Names Dr Jeffrey W Sherman Executive Vice President and Chief Medical Officer 12821 2